The FDA has approved Eli Lilly's Jaypirca (pirtobrutinib) for use as a first-line treatment in adult patients with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) without the 17p deletion. This approval is based on the Phase 3 BRUIN CLL-313 trial, which showed Jaypirca significantly delays disease progression compared to chemoimmunotherapy, with a favorable safety profile. Jaypirca is the first non-covalent BTK inhibitor approved for this use, offering a new targeted therapy option for patients. Lilly continues to study Jaypirca in multiple ongoing Phase 3 trials to further define its role in CLL/SLL treatment.
Following the FDA's expanded approval of Lilly's Jaypirca for certain leukemia patients, Eli Lilly And Co shares are trading slightly lower on Pluang. As of Oct 03, 2026 02:21 WIB, LLY is priced at USD 1,145.85, down 0.48% for the day. The stock holds a market cap of $1.02 trillion and a dividend yield of 0.6%, with typical investor hold time around 93 days.
Eli Lilly reported a 47.7% revenue increase to $22.97 billion in Q2 2026, surpassing expectations and raising its full-year revenue guidance to $85-$87 billion. The company’s stock trades near $1,185 with a 24/7 Wall St. price target of $1,401, sugge...
Eli Lilly announced promising mid-stage trial results for EloraTZP, a new obesity drug that led to up to 23.3% weight loss in overweight or obese type 2 diabetes patients after 48 weeks, outperforming Novo Nordisk's tirzepatide alone. The drug also s...
Foghorn Therapeutics saw its price target cut from $12 to $5 after it and Eli Lilly decided not to advance key cancer drug programs. The companies will not continue development of FHD-909 or a selective SMARCA2 degrader, ending their collaboration. F...
Eli Lilly's Foundayo (orforglipron) showed in post-hoc analyses of the ATTAIN-1 trial a significant reduction in predicted 10-year risks of type 2 diabetes and cardiovascular disease among adults with obesity or overweight with related health issues....
The Phase 3 ACHIEVE-4 trial found that Foundayo (orforglipron) reduced the risk of major cardiovascular events by 16% and cardiovascular death by 53% compared to insulin glargine in adults with type 2 diabetes and obesity. It also improved blood suga...
